Biologics Regulatory CERAMENT® V application in the U.S. transferred to the De Novo process byWill SandbergDecember 2, 2025
Hospitals Shimadzu Medical Systems USA announces the release of the SC15 byJosh SandbergNovember 24, 2025
Recon Regulatory Robotics Zimmer Biomet Receives U.S. FDA Clearance for Enhanced Version of ROSA® Knee Robotic Technology byJosh SandbergNovember 14, 2025
Robotics LEM Surgical Announces Major US Clinical Milestone With Dynamis Robotic Surgical System byWill SandbergNovember 12, 2025
Spine Top Stories Amber Implants Appoints Vincent Gardès as Chief Executive Officer to Drive Commercial Launch of VCFix® Spinal System byTim AllenNovember 6, 2025
Biologics Spine Fziomed Initiates Commercialization of Oxiplex Gel in the United States byJosh SandbergNovember 5, 2025
Financial Hospitals Regulatory Top Stories Bioretec’s RemeOs™ Screw LAG Solid Receives CMS Transitional Pass-Through Payment in the US byNoah SimmonsOctober 1, 2025
Regulatory As shutdown begins, FDA to stop accepting new drug submissions byWill SandbergOctober 1, 2025
Financial Regulatory Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients byWill SandbergSeptember 30, 2025
Biologics Extremities The United States Orthobiologics Market offers significant growth opportunities in segments like Cartilage Repair, Bone Grafts and Substitutes, Bone Growth Stimulators, Soft Tissue Biologics, and Viscosupplementation. Key companies and strategic insights enable business expansion and competitive strategy development byWill SandbergSeptember 30, 2025
